Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Mild Cognitive Impairment (MCI), Cognition, Brain Aging, Microbiome Dysbiosis, Leaky Gut Syndrome, Gut Inflammation, Inflammaging
Interventions: LpD3.5, Placebo; Dietary Supplement
Lead sponsor: University of South Florida; Other
Eligibility: 60 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
Interventions: US-ATG-F, Placebo; Biological
Lead sponsor: Neovii Biotech; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 26
States / cities: Duarte, California • Stanford, California • Gainesville, Florida + 20 more

Conditions: Hernia Abdominal Wall, Botox Injection, Hernia Incisional Ventral, Hernia Repair With Compartment Syndrome, Hernia Surgery, Hernia, Hernia Incisional
Interventions: OnabotulinumtoxinA Injection, Saline (placebo) Injection, OnabotulinumtoxinA, 0.9 % Normal Saline, Open Ventral Hernia Repair; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Meningococcal Immunisation, Healthy Volunteers
Interventions: Multicomponent Meningococcal B Vaccine, Meningococcal Group B Vaccine MenB, Meningococcal Group B Vaccine (recombinant deoxyribonucleic acid [rDNA], component, adsorbed), Placebo, Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine; Drug
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 50 Years
Enrollment: 576 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Guntersville, Alabama • San Diego, California • Tampa, Florida + 5 more

Conditions: Atrophic Vaginitis
Interventions: Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 21
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Hypercholesterolemia, Dyslipidemia
Interventions: Placebo, PF-04950615 (RN316); Other · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 29
States / cities: Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more

Conditions: Primary Sclerosing Cholangitis
Interventions: BRS201, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions: Vaginal Cream with Applicator; Drug
Lead sponsor: Jefferson Drapkin; Other
Eligibility: 60 Years to 90 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Chronic Idiopathic Urticaria
Interventions: AZD1981, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infantile Colic
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: The Archer-Daniels-Midland Company; Industry
Eligibility: 3 Weeks to 12 Weeks
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Healthy
Interventions: cannabidiol, Placebo; Drug
Lead sponsor: Castleton University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Castleton, Vermont

Conditions: Migraine
Interventions: AMG 333, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Endothelial Dysfunction, Aging
Interventions: Aronia full spectrum - half dose, Aronia full spectrum - full dose, Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Major Depressive Disorder
Interventions: Fisher Wallace Cranial Electrotherapy Stimulator (Active Device), Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device); Device
Lead sponsor: Fisher Wallace Laboratories; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Peripheral Vascular Disease
Interventions: Remodulin (treprostinil sodium) Injection; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 4
States / cities: Springfield, Illinois • Worcester, Massachusetts • Albany, New York + 1 more

Conditions: Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions: Denosumab Inj 60 mg/ml, Placebo; Drug · Other
Lead sponsor: Thomas Nickolas, MD MS; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • New York, New York

Conditions: Cognitive Disorders, HIV Infections
Interventions: Thioctic acid, Selegiline hydrochloride; Drug
Lead sponsor: The Dana Foundation; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York

Conditions: MAJOR DEPRESSIVE DISORDER
Interventions: INFLUENZA VACCINE, NaCl-saline placebo; Biological · Other
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: High Triglycerides
Interventions: NST-1024, Placebo; Drug · Other
Lead sponsor: NorthSea Therapeutics B.V.; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 31
States / cities: Birmingham, Alabama • Daphne, Alabama • Tempe, Arizona + 28 more

Conditions: Overweight and Obesity
Interventions: Epitomee Capsule, Control-Placebo; Device · Other
Lead sponsor: Epitomee medical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 279 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 9
States / cities: Birmingham, Alabama • Chicago, Illinois • Kansas City, Kansas + 6 more

Conditions: Post-Traumatic Stress Disorder (PTSD)
Interventions: Oxytocin nasal spray, Saline nasal spray, Brief Cognitive-Behavioral Conjoint Therapy; Drug · Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Ankylosing Spondylitis
Interventions: Sarilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Birmingham, Alabama • Anaheim, California • Los Angeles, California + 23 more

Conditions: Cocaine Dependence
Interventions: Nepicastat, Placebo; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • Denver, Colorado + 7 more

Conditions: Painful Lumbosacral Radiculopathy
Interventions: VX-548, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 54
States / cities: Phoenix, Arizona • Bakersfield, California • Banning, California + 48 more

Search by objective public record fields.

LpD3.5 Intervention Study in Older Adults- LISA-I Trial

Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Preoperative BOTOX® Injection for Large Ventral Hernia Repair

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Detoxification of the Liver In PSC (Dolphin)

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines

Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief

Cannabidiol and Autonomic Function at Rest

Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines

Effects of Aronia Berries on Vascular Endothelial Function and the Gut Microbiota in Middle-Aged/Older Adults

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

A Study of Thioctic Acid and Deprenyl in HIV-Infected Patients With Dementia

Influenza Challenge in Mood Disorders

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia

The Effect of Epitomee Capsule on Body Weight in Patients With Overweight and Obesity

Examining Intranasal Oxytocin Augmentation of Brief Couples Therapy for Veterans With PTSD

Dose Ranging Study to Evaluate the Efficacy and Safety of SAR153191 (REGN88) in Patients With Ankylosing Spondylitis

A Multi-Center Trial of Nepicastat for Cocaine Dependence

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)